B2M and neoplasm: These results underscore a potential clinical development strategy by combining anti-β2M mAbs and BTZ to treat MM patients, which could lower the doses of BTZ and anti-β2M mAbs needed while enhancing their anti-tumor effects, and more importantly, reduce BTZ- and anti-β2M mAb-induced toxicity.